

## Appendix 3Y

### Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Clarity Pharmaceuticals Ltd
<b>ABN</b>	36 143 005 341

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Alan John Taylor
<b>Date of last notice</b>	26 November 2024

#### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	n/a
<b>Date of change</b>	1 July 2025

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>No. of securities held prior to change:</b>  Dr Alan Taylor</p> <p>A.C.N 136 437 913 Pty Ltd ATF the Taylor Family Trust</p> <p>Sally Taylor (spouse of Dr Taylor)</p>	<ul style="list-style-type: none"> <li>• 1,000,000 options exercisable at \$0.9375 each on or before 1 July 2025</li> <li>• 1,083,226 options exercisable at \$0.508 each on or before 24 November 2027</li> <li>• 1,134,630 options exercisable at \$0.793 each on or before 24 November 2028</li> <li>• 630,351 options exercisable at \$0.721 each on or before 24 November 2028</li> <li>• 258,246 options exercisable at \$5.505 each on or before 20 November 2029</li> <li>• 482,502 options exercisable at \$5.005 each on or before 20 November 2029</li> <li>• 1,626,778 fully paid ordinary shares</li> <li>• 13,266,660 fully paid ordinary shares</li> <li>• 800,000 fully paid ordinary shares</li> </ul>
<p><b>Class</b></p>	<p>Options and Shares</p>
<p><b>Number acquired</b></p>	<p>592,373 fully paid ordinary shares</p>
<p><b>Number disposed</b></p>	<p>1,000,000 options exercisable at \$0.9375 each on or before 1 July 2025</p>
<p><b>Value/Consideration</b>  Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>\$937,500 being the exercise price on options exercised</p>
<p><b>No. of securities held after change:</b>  Dr Alan Taylor</p> <p>A.C.N 136 437 913 Pty Ltd ATF the Taylor Family Trust</p> <p>Sally Taylor (spouse of Dr Taylor)</p>	<ul style="list-style-type: none"> <li>• 1,083,226 options exercisable at \$0.508 each on or before 24 November 2027</li> <li>• 1,134,630 options exercisable at \$0.793 each on or before 24 November 2028</li> <li>• 630,351 options exercisable at \$0.721 each on or before 24 November 2028</li> <li>• 258,246 options exercisable at \$5.505 each on or before 20 November 2029</li> <li>• 482,502 options exercisable at \$5.005 each on or before 20 November 2029</li> <li>• 2,219,151 fully paid ordinary shares</li> <li>• 13,266,660 fully paid ordinary shares</li> <li>• 800,000 fully paid ordinary shares</li> </ul>

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of options on a cashless basis applying a share price of \$2.2999 being 5-day VWAP prior to instruction to exercise.
---	---

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	n/a
<b>Nature of interest</b>	n/a
<b>Name of registered holder (if issued securities)</b>	n/a
<b>Date of change</b>	n/a
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	n/a
<b>Interest acquired</b>	n/a
<b>Interest disposed</b>	n/a
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	n/a
<b>Interest after change</b>	n/a

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	n/a
<b>If prior written clearance was provided, on what date was this provided?</b>	n/a

<sup>+</sup> See chapter 19 for defined terms.

For personal use only